Tirzepatide (Mounjaro) Pharmacology Podcast

Real Life Pharmacology - Pharmacology Education for Health Care Professionals

Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist

Education, Health & Fitness, Medicine

5 • 716 Ratings

🗓️ 12 January 2023

⏱️ 16 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

On this episode I discuss the pharmacology of tirzepatide. I'm appreciative of Derek Borkowski who operates Pyrls for providing a free PDF of the 2023 ADA Diabetes Guidelines when you subscribe for an account at Pyrls.com/rlp - Tirzepatide makes its first appearance in the diabetes guidelines for its ability to promote weight loss.

Tirzepatide is a combination GIP and GLP-1 agonist that is currently indicated for diabetes with reductions of A1C in the range of about 2 points.

Much like GLP-1 agonists, tirzepatide can cause GI upset and other gastrointestinal adverse effects like diarrhea.

Tirzepatide doesn't have a large number of drug interactions which is nice. Corticosteroids can counteract its blood sugar-lowering effects while sulfonylureas and insulin may significantly increase the risk for hypoglycemia.

Transcript

Click on a timestamp to play from that location

0:00.0	Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host, Eric Christensen.
0:05.1	Thank you so much for listening today. Go check out Real Life Pharmacology.com. Get your free 31-page
0:11.2	PDF on the top 200 drugs. Simply an email to subscribe to our mailing list. We'll get you access to that.
0:18.4	So a great resource, great refresher if you're taking
0:21.7	port exams, going through pharmacology courses, or just looking for that little clinical
0:27.0	refresher. So again, real-life pharmacology.com, sign up for the free Top 200 study guide.
0:34.5	All right, the drug of the day today is TIRS appetite.
0:44.4	Brand name of this medication is Monjaro. I have heard pronounced a few different ways, but I believe that is the correct pronunciation. This is a newer diabetes agent. So more specifically, used
0:53.1	for type 2 diabetes, its classification is
0:57.4	glucose-dependent insulinotropic polypeptide. That is commonly abbreviated as GIP, and it is a
1:09.5	combination with a glucagon-like peptide receptor agonist.
1:15.1	So that is GLP-1.
1:17.2	So I've talked about GLP-1s extensively in previous podcasts,
1:22.3	semi-glutide, Lyraglutide, I believe I've covered those for sure.
1:27.6	So you can go back and get a little bit more depth with that.
1:31.2	There are quite a few similarities.
1:34.2	And as far as the adverse effect profile,
1:36.3	which I'll discuss coming up here,
1:38.4	it is very, very similar to the gLP ones
1:43.3	as far as adverse effect profile.
1:45.7	So mechanistically, what do these two things do?
1:51.1	So ultimately you're going to end up with increased glucose-dependent insulin release.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.